FY27 Budget Proposal Signals Continued Pressure on NIH, NSF, FDA — Raising Stakes for US Innovation

For the life sciences ecosystem, the proposal sends a clear signal: continued downward pressure on federal investment in biomedical research, scientific training, and regulatory capacity. 

At the National Institutes of Health (NIH), the Administration proposes a $5 billion reduction (approximately 10–12%), alongside a broader 12.5% cut to HHS funding overall. This follows prior proposals to significantly restructure NIH and consolidate institutes, reflecting a sustained effort to reshape the agency’s scope and priorities. 

Within NIH, key programmatic impacts include: 

• Continued pressure on R01 funding, the backbone of investigator-initiated research 

• Reduced capacity for early-career grants (K awards) and training programs (T32, F-series fellowships) 

• Fewer new and competing awards, further tightening already competitive success rates 

The budget also proposes a significant reduction to ARPA-H, cutting funding from approximately $1.5 billion to $945 million, scaling back one of the federal government’s primary vehicles for high-risk, breakthrough biomedical innovation.  

At the National Science Foundation (NSF), the FY27 request reflects a constrained topline with programmatic realignment, prioritizing select “high-impact” research while reducing or eliminating funding for certain STEM education and workforce programs. Historically, these programs have supported: 

• Graduate Research Fellowships (GRFP) 

• Traineeships and early-career investigator awards 

• Foundational basic science that underpins long-term innovation 

The proposed changes raise concerns about reduced support for early-stage discovery science and the future STEM workforce pipeline. 

The budget also carries important implications for the Food and Drug Administration (FDA). While detailed topline changes are embedded within the broader HHS request (approximately $111 billion in discretionary funding), the Administration emphasizes cost savings and efficiency across agencies. In practice, constrained FDA funding could: 

• Limit hiring of scientific reviewers and inspectors 

• Slow review timelines for new drugs and biologics 

• Increase reliance on user fees, shifting cost burdens to industry 
  
  

Implications for Research, Training, and Innovation 

• Fewer NIH R01 and equivalent grants, slowing the pace of discovery and reducing funded investigators 

• Reduced support for early-career scientists, including K awards, fellowships, and NSF traineeships 

• Scaling back of high-risk innovation programs like ARPA-H, limiting breakthrough research opportunities 

• Constraints on academic research infrastructure, particularly due to pressure on indirect costs and institutional funding 

• Potential delays in regulatory review and product development due to constrained FDA capacity 

• Erosion of global competitiveness, as other nations expand investment in science and biotechnology 

MichBio Perspective 

Federal investment in NIH, NSF, and FDA is foundational to Michigan’s life sciences ecosystem - fueling discovery, training talent, and enabling companies to bring new therapies to market. 

While the Administration’s proposal reflects broader fiscal priorities, sustained reductions across these agencies risk weakening the innovation pipeline end-to-end - from basic research and workforce development to product approval. 

As Congress begins the appropriations process, maintaining robust, predictable funding across NIH, NSF, and FDA - particularly for investigator-led research, early-career training, and regulatory capacity - will be essential to preserving U.S. leadership in biotechnology and ensuring continued delivery of new treatments to patients.

It is important to note that Congress has historically rejected or mitigated proposed cuts to science and research programs, often restoring funding through the appropriations process. However, doing so requires sustained engagement. With appropriations negotiations ahead, grassroots advocacy will be critical - beginning with MichBio’s upcoming Capitol Hill Fly-In next week, where Michigan’s life sciences leaders, including two early-stage companies, will directly engage policymakers on the importance of maintaining strong federal support for biomedical research and innovation.